Cancer drug sales lift Genentech quarterly profit
11th Jan 2006, 17:50 GMT
NEW YORK (Reuters) - Genentech Inc. on Tuesday reported fourth-quarter profit rose 64 percent on strong sales of its cancer medicines, but colon cancer drug Avastin fell short of Wall Street expectations and the company's shares fell more than 2 percent after hours.
Cancer drug sales lift Genentech quarterly profit related news:
- Cancer drug sales lift Genentech quarterly profit — Pharmaceuticals News from StratCenter.com
- Cancer drug sales lift Genentech quarterly profit (Reuters) — Yahoo! News: Earnings News
- Cancer Drugs Lift Earnings at Genentech — NYT > Business
- Genentech sales and profit soar — Latest news from San Francisco Business Times
- Genentech: Avastin sales hard to predict — MarketWatch.com - Top Stories
- Genentech Falls 4% on Avastin — Red Herring
- Former worker sues Genentech over drug marketing — News -- SiliconValley.com
- Ex-Worker Sues Genentech Over Marketing — washingtonpost.com -
- Intel expected to show higher quarterly profit (Reuters) — Yahoo! News: Semiconductor Industry & Servers
- Intel expected to show higher quarterly profit — Reuters: Business